Navigation Links
CureHIV Reaches Out to Bill and Melinda Gates to Fund LiSAVIOR
Date:3/28/2008

HILTON HEAD ISLAND, S.C., March 28 /PRNewswire/ -- Dr. Roger Kenneth Hershline PhD MD, the CEO of Global Humanceuticals, Inc. and founder and chairman of the not-for-profit public charity CureHIV.us, announces today that he is reaching out to Bill and Melinda Gates for funding from their Grand Challenges in Global Health initiative. The monies will be used to begin clinical studies of a new drug and treatment method, LiSAVIOR.

This unique new drug is also known as compound NIAID #11039 and has received a patent from the United States with patent number: 6,821,958 on November 23, 2004. Also, the World International Patent Organization published the International Application Number as PCT/US2005/039528 on November 5, 2006.

Dr. Hershline hosted Session V at the World Aids Day Conference China from December 1 to December 3, 2006, to initially present LiSAVIOR.

The proposed roadblock to cure HIV is that current drug and vaccination treatments do not treat the growth of HIV in the gastrointestinal tract. HIV virus multiplies and mutates in the gastrointestinal tract and then is reabsorbed into the blood. This process is known to occur when HIV infection results from the use of contaminated needles or during sexual intercourse. The gastrointestinal tract is comprised of the mouth and its structures, the pharynx, the esophagus, the stomach, the small intestines, the large intestines and the anus.

The proposed solution to overcome this roadblock is the oral clinical use of LiSAVIOR, a drug that is an early stage HIV life cycle inhibitor. LiSAVIOR blocks not only viral entry into cells but also cell-to-cell transfer of the virus. LiSAVIOR is proposed to be used alone or with any known HIV drug and vaccine therapy.

Pre-clinical efficacy testing of LiSAVIOR has shown that the effective concentration of LiSAVIOR is found to be equivalent to diluting a 1% solution of LiSAVIOR one million times. LiSAVIOR is a dry, palatable, non-toxic powd
'/>"/>

SOURCE CureHIV.us
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Cancer Pioneer Reaches Key Agreement on Colon Cancer Drug OncoVAX(R)
2. CSL Behring Reaches Primary Endpoint in Clinical Study of C1-INH for Treatment of Hereditary Angioedema
3. Arizona Heart Hospital Reaches Settlement Regarding Clinical Research Matter
4. Enrollment Reaches 110 Patients in Investigator Initiated, Randomized Trial of OrbusNeichs Genous(TM) Bio-Engineered R Stent(TM)
5. Gates Foundation Seeks Proposals for Innovative Global Health Research
6. Dr. Rajeev Venkayya Joins Gates Foundation as Director of Global Health Delivery
7. Study of Pathwork Diagnostics Tissue of Origin Test Published in the Journal of Molecular Diagnostics: Investigates Test Reproducibility in Multiple Labs to Determine Primary Tumor in Cancer Cases
8. Researcher Investigates Disparities in Doctor-Patient Information Exchange During Clinical Trial Offers
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... -- ChinaMarketResearchReports.com adds "China Orthopedic Instrument Industry Report, 2013-2015" ... (Photo: http://photos.prnewswire.com/prnh/20140115/MN46792 ) Benefiting from aging ... China,s orthopedic instrument industry has seen rapid ... from 3.28 billion yuan in 2006 to 9.85 billion ...
(Date:1/15/2014)... As health officials across the Midwest warn against the widespread ... Michigan will offer free diagnostic testing for ... to administer tests and, in some cases, fill the matching ... the study. The Grand Rapids, Mich. ...
(Date:1/15/2014)... , Jan. 15, 2014  Celsion Corporation (the "Company") (NASDAQ: ... commitments from institutional investors to purchase an aggregate of ... an at-the-market registered direct offering, led by a dedicated ... definitive purchase agreements with these investors pursuant to which ...
Breaking Medicine Technology:Orthopedic Instrument Industry in China Markets Forecast to 2015 2Orthopedic Instrument Industry in China Markets Forecast to 2015 3Meijer Pharmacy Offers Free Flu, Strep Testing as Influenza Cases Rise Across the Midwest 2Meijer Pharmacy Offers Free Flu, Strep Testing as Influenza Cases Rise Across the Midwest 3Celsion Corporation Announces $15 Million At-The-Market Registered Direct Offering 2Celsion Corporation Announces $15 Million At-The-Market Registered Direct Offering 3
... Feb. 24, 2011 HeartWare International, Inc. (Nasdaq: ... less invasive, miniaturized circulatory support technologies that are revolutionizing ... of $20.9 million for the fourth quarter ended December ... for the fourth quarter of 2009, and revenues of ...
... N.J. and EMERYVILLE, Calif., Feb. 24, 2011 ... ONXX ) today announced the companies ... randomized, double-blind, placebo-controlled trial evaluating Nexavar® (sorafenib) tablets ... versus placebo plus capecitabine for the treatment of ...
Cached Medicine Technology:HeartWare International Reports Fourth Quarter 2010 Revenues of $20.9 Million; 71% Increase From $12.2 Million In Fourth Quarter 2009 2HeartWare International Reports Fourth Quarter 2010 Revenues of $20.9 Million; 71% Increase From $12.2 Million In Fourth Quarter 2009 3HeartWare International Reports Fourth Quarter 2010 Revenues of $20.9 Million; 71% Increase From $12.2 Million In Fourth Quarter 2009 4HeartWare International Reports Fourth Quarter 2010 Revenues of $20.9 Million; 71% Increase From $12.2 Million In Fourth Quarter 2009 5HeartWare International Reports Fourth Quarter 2010 Revenues of $20.9 Million; 71% Increase From $12.2 Million In Fourth Quarter 2009 6Bayer and Onyx Begin Enrollment in Phase 3 Trial of Nexavar in Combination With Chemotherapy Agent Capecitabine for Patients With Advanced Breast Cancer 2Bayer and Onyx Begin Enrollment in Phase 3 Trial of Nexavar in Combination With Chemotherapy Agent Capecitabine for Patients With Advanced Breast Cancer 3Bayer and Onyx Begin Enrollment in Phase 3 Trial of Nexavar in Combination With Chemotherapy Agent Capecitabine for Patients With Advanced Breast Cancer 4Bayer and Onyx Begin Enrollment in Phase 3 Trial of Nexavar in Combination With Chemotherapy Agent Capecitabine for Patients With Advanced Breast Cancer 5Bayer and Onyx Begin Enrollment in Phase 3 Trial of Nexavar in Combination With Chemotherapy Agent Capecitabine for Patients With Advanced Breast Cancer 6Bayer and Onyx Begin Enrollment in Phase 3 Trial of Nexavar in Combination With Chemotherapy Agent Capecitabine for Patients With Advanced Breast Cancer 7
(Date:7/9/2014)... PROVIDENCE, R.I. Researchers have found that fecal ... difficile in immunocompromised patients. This is the result ... gastroenterologist in the Center for Women,s Gastrointestinal Medicine at ... have been published online in advance of print in ... Clostridium difficile , or C. diff , has ...
(Date:7/9/2014)... and subjective, the human brain turns them into ... different senses, situations and even people, reports a ... , "We discovered that fine-grained patterns of neural ... the brain associated with emotional processing, act as ... feeling," says Anderson, associate professor of human development ...
(Date:7/9/2014)... (July 8, 2014) Researchers from Montefiore Medical ... Medicine of Yeshiva University will present new findings ... July 12 July 17 in Copenhagen, Denmark. Data ... could prompt transition from cognitive normality to mild cognitive ... Einstein Aging Study , established in 1980 to ...
(Date:7/9/2014)... have a reputation for being highly toxic, but when used ... being found to offer potential health benefits in a range ... A new compound (AP39), designed and made at the University ... targeting delivery of very small amounts of the substance to ... in Exeter have already found that the compound protects mitochondria ...
(Date:7/9/2014)... conducted by researchers at Tufts University School of Dental ... and developmental disabilities, the likelihood of having cavities decreased ... The findings, published in the July/August issue of ... designed to address the oral health of individuals in ... records of 107 patients at one of the eight ...
Breaking Medicine News(10 mins):Health News:Women's Medicine Collaborative examines safety of fecal transplant to treat C. difficile 2Health News:Study cracks how the brain processes emotions 2Health News:Investigators from Montefiore and Einstein to present data at 2014 Alzheimer's Association International Conference 2Health News:Investigators from Montefiore and Einstein to present data at 2014 Alzheimer's Association International Conference 3Health News:Rotten egg gas holds key to healthcare therapies 2Health News:Adults with special needs see gains, challenges with long term oral care 2Health News:Adults with special needs see gains, challenges with long term oral care 3
... ... that seeks to accelerate the transformation of Upstate New York’s economy into an ... number of small, innovation-oriented companies. , ... Syracuse, NY (PRWEB) February 4, 2010 -- Veteran ...
... Preventive efforts needed to reduce transmission from mother to ... -- Rates of HIV infection in infants are significantly ... measures are needed to reduce the disparity, a new ... infants has declined overall, among black babies, the rate ...
... ATLANTA , Feb. 4 For the ... performed a rigorous assessment of SIS Rules-Based Charging (RBC), ... and determined that it meets the stringent standards of ... quality and usability, price, value, and customer and technical ...
... , , EDF Testifies 20 Million+ Residents ... SACRAMENTO, Calif. , Feb. 4 Environmental ... Air Quality Standard (NAAQS) for ozone pollution from 75 to ... 60-fold and reduce asthma cases 50-fold, according to analyses by the ...
... Psychological Association urged both the Pentagon and Congress today to ... serving openly in the military, noting that there are decades ... morale. "While we were heartened by the congressional testimony ... believe that a year to study the matter and another ...
... UCSF ... reach and fertilize the egg, a finding that has implications on both treating male infertility ... (Vocus) ... ability of human sperm to reach and fertilize the egg, a finding that has implications ...
Cached Medicine News:Health News:Silicon Valley Entrepreneur Launches Startup to Accelerate Tech Entrepreneurship in Upstate New York 2Health News:Silicon Valley Entrepreneur Launches Startup to Accelerate Tech Entrepreneurship in Upstate New York 3Health News:Silicon Valley Entrepreneur Launches Startup to Accelerate Tech Entrepreneurship in Upstate New York 4Health News:Silicon Valley Entrepreneur Launches Startup to Accelerate Tech Entrepreneurship in Upstate New York 5Health News:Black and Hispanic Infants Much More Likely to Have HIV 2Health News:SIS Rules-Based Charging Solution Successfully Peer Reviewed by HFMA for Third Consecutive Year 2Health News:SIS Rules-Based Charging Solution Successfully Peer Reviewed by HFMA for Third Consecutive Year 3Health News:Stronger Ozone Standard Could Dramatically Reduce Asthma, Premature Deaths 2Health News:Stronger Ozone Standard Could Dramatically Reduce Asthma, Premature Deaths 3Health News:Pentagon and Congress should act quickly to end gay military ban, APA says 2Health News:UCSF Researchers Identify Regulator of Human Sperm Cells 2Health News:UCSF Researchers Identify Regulator of Human Sperm Cells 3Health News:UCSF Researchers Identify Regulator of Human Sperm Cells 4
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
Medicine Products: